Key result
Chemotherapy with COP, R-CHOP, and R-CHASE resulted in complete remission of primary cardiac B cell lymphoma, which was sustained for 1 year.
Why the study?
Primary cardiac lymphoma is rare and increasingly seen in immunocompromised hosts, but a considerable proportion still occurs in immunocompetent patients.
Case Report (n=1)
Primary cardiac B cell lymphoma can be successfully treated with chemotherapy, and multimodality imaging including optical coherence tomography is valuable for assessing tumor extension and predicting ischemic complications.
Answers are grounded in this paper and cite their sources.
May support chemotherapy in primary cardiac B-cell lymphoma; leaves open need for confirmatory studies before practice change.
Primary cardiac lymphoma is a rare entity of extranodal lymphoma and is observed with increasing frequency in immunocompromised hosts. However, a considerable proportion of cardiac lymphomas still occur in immunocompetent patients. We report the case of a 55-year-old immunocompetent Japanese man with a large amount of pericardial fluid and the presentation of heart failure secondary to primary cardiac B cell lymphoma, which was diagnosed by cytological examination of pericardial fluid and imaging. The right atrium, right ventricle and pericardium were affected by the tumour, which encased the mid/distal portion of the right coronary artery (RCA). Pretreatment optical coherence tomography of the RCA demonstrated no tumour extension into the vascular structure but a focal mural thrombus. We initiated chemotherapy (steroid therapy then COP at half dose/R-CHOP/R-CHASE) [COP (C: Cyclophosphamide, O: Oncovin, P: Prednisolone) R-CHOP (R: Rituximab, C: Cyclophosphamide, H: Doxorubicin Hydrochloride, O: Oncovin, P: Prednisolone) R-CHASE (R: Rituximab, C: Cyclophosphamide, HA: high dose Cytarabine, S: Steroid, E: Etoposide)]with administration of low-dose aspirin to prevent possible ischaemic events. The patient had a good clinical course without adverse events except for transient pericarditis.
No takes yet. Share an insight, caveat, or question.
Miyawaki et al. (2021) conducted a case report in Primary cardiac B cell lymphoma (n=1). Chemotherapy (COP, R-CHOP, R-CHASE) was evaluated on Tumor response. Chemotherapy with COP, R-CHOP, and R-CHASE resulted in complete remission of primary cardiac B cell lymphoma, which was sustained for 1 year.
Synapse has enriched 10 related papers. Consider them for comparative context: